# Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC

> **NCT03673735** · PHASE3 · WITHDRAWN · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC**

## Conditions studied

- Squamous Cell Head and Neck Carcinoma

## Interventions

- **DRUG:** Durvalumab
- **RADIATION:** radiotherapy
- **DRUG:** Placebo
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT03673735
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-06
- **Primary completion:** 2026-07
- **Final completion:** 2027-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company withdrew interest
- **Last updated:** 2021-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03673735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03673735, "Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03673735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*